SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis ...
TipRanks on MSN
4D Molecular Therapeutics Advances in Macular Degeneration Treatment: A Phase 3 Study Update
D Molecular Therapeutics, Inc. (($FDMT)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled A Phase ...
ONL Therapeutics announced the first patient has been randomized in its phase 2 GALAXY ( NCT06659445) trial evaluating ...
Please provide your email address to receive an email when new articles are posted on . NEW YORK — Anterior chamber paracentesis may be an effective option to reduce IOP spikes after intravitreal ...
Please provide your email address to receive an email when new articles are posted on . Intravitreal injections have a large environmental impact, estimated to be around 210 million kg of CO 2 ...
STOCKHOLM — Simple changes, like minimizing patient visits and reducing the use of nonsterile gloves, can make a big difference in the environmental impact of intravitreal injections without ...
Application of topical anesthetic drops may be more effective at reducing pain caused by intravitreal injection, according to an OSN SuperSite report. Gregory R. Blaha, MD, PhD, one of the study’s ...
MedPage Today on MSN
Litigation Involving Eye Injections Appears to Be Rare, but Trends Are Clear
While rare, litigation regarding the use of intravitreal injections often involved the three key areas of procedural lapses, ...
Adipose tissue–derived “stem cells” have been increasingly used by “stem-cell clinics” in the United States and elsewhere to treat a variety of disorders. We evaluated three patients in whom severe ...
SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial SPVN20 aims to restore visual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback